Article
Biochemistry & Molecular Biology
Yun-Fei Xu, Xu Chen, Zhao Yang, Peng Xiao, Chun-Hua Liu, Kang-Shuai Li, Xiao-Zhen Yang, Yi-Jing Wang, Zhong-Liang Zhu, Zhi-Gang Xu, Sheng Zhang, Chuan Wang, You-Chen Song, Wei-Dong Zhao, Chang-He Wang, Zhi-Liang Ji, Zhong-Yin Zhang, Min Cui, Jin-Peng Sun, Xiao Yu
Summary: The study demonstrates the role of PTP-MEG2 in controlling multiple steps of catecholamine secretion by regulating substrate selectivity and dephosphorylating specific sites to modulate fusion pore opening. Structural and biochemical analyses highlight the interaction between PTP-MEG2 and its substrates, providing mechanistic insights into complex exocytosis processes.
Article
Cardiac & Cardiovascular Systems
Mauro Siragusa, Alberto Fernando Oliveira Justo, Pedro Felipe Malacarne, Anna Strano, Akshay Buch, Barbara Withers, Kevin G. Peters, Ingrid Fleming
Summary: The study found that inhibition of VE-PTP can significantly lower systolic and diastolic blood pressure in diabetic patients by increasing NO production and enhancing eNOS activity. In addition, VE-PTP can also directly improve endothelial function and decrease blood pressure by dephosphorylating eNOS Tyr81. This suggests that VE-PTP inhibition may represent a promising therapeutic option for diabetes-induced endothelial dysfunction and hypertension.
CARDIOVASCULAR RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Na Young Kim, Gautam Sethi, Jae-Young Um, Kwang Seok Ahn
Summary: EPBS can potentially function as an anti-cancer agent by inducing apoptosis and autophagy when targeting the SHP-1/STAT3 pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Cell Biology
Fang Hao, Chen Wang, Christine Sholy, Min Cao, Xunlei Kang
Summary: Protein tyrosine phosphatases play a crucial role in modulating cellular functions and have been linked to human leukemia; however, the impact of these phosphatases and their mutations on leukemia remains controversial.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jiayu Fang, Yuqin Zhang, Caihu Huang, Runhui Lu, Jie Yu, Ran Chen, Yanli Wang, Xian Zhao, Jianxiu Yu, Jian Huang
Summary: Glycosylation modification regulates the biological function of RPTP alpha and promotes tumor development.
Article
Biochemistry & Molecular Biology
Ji-Lin Chen, Pei-Yi Chu, Chun-Teng Huang, Tzu-Ting Huang, Wan-Lun Wang, Yu-Hsuan Lee, Yuan-Ya Chang, Ming-Shen Dai, Chung-Wai Shiau, Chun-Yu Liu
Summary: This study demonstrates that SHP-1 agonist has potent anti-tumor effects in DLBCL and may serve as a potential therapeutic drug by targeting SHP-1/p-Lyn.
MOLECULAR MEDICINE
(2022)
Article
Cell Biology
Alberto Fernando Oliveira Justo, Pedro Paulo Luciano Afonso
Summary: VE-PTP directly regulates eNOS, affecting phosphorylation reactions, and the use of a VE-PTP inhibitor can have an impact on blood pressure in diabetic patients.
JOURNAL OF CELL COMMUNICATION AND SIGNALING
(2021)
Article
Biochemistry & Molecular Biology
Yamei Hu, Fangfang Liu, Xuechao Jia, Penglei Wang, Tingxuan Gu, Hui Liu, Tingting Liu, Huifang Wei, Hanyong Chen, Jiuzhou Zhao, Ran Yang, Yingying Chen, Zigang Dong, Kangdong Liu
Summary: A novel STAT3 inhibitor, periplogenin, was identified in this study, showing significant inhibition of ESCC growth in vitro and in vivo. It has the potential to be utilized for the treatment and prevention of ESCC.
Article
Biochemistry & Molecular Biology
Evangelia Papadimitriou, Vasiliki K. Kanellopoulou
Summary: Protein tyrosine phosphatase receptor zeta 1 (PTPRZ1) is highly expressed during embryonic development but limited in adulthood. It plays a role in oligodendrocytes' survival and maturation in the central nervous system. In gliomas, PTPRZ1 is significantly upregulated and studied as a potential cancer driver and therapy target. However, its functional significance and tumor-suppressor role in other cancer types need further investigation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
QinLei Gu, Kenneth S. Tung, Ulrike M. Lorenz
Summary: To achieve a healthy and functional immune system, there is a delicate balance between the activation of Tcon cells and the suppression by Treg cells. SHP-1 plays a role in modulating this balance by regulating Tcon cell resistance to Treg-mediated suppression. However, the role of SHP-1 in Treg function is still not fully understood.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Endocrinology & Metabolism
Adrienn Markovics, Sydney Lupo, Niyati Patel, Katalin Mikecz, D. Rick Sumner, Ryan D. Ross
Summary: This study found that Shp1 overexpression leads to increased bone mass and improved mechanical properties in mice, but only in 28-day-old mice. Female SHP1-Tg mice showed higher trabecular bone volume, trabecular number, and connectivity density compared to wildtype mice.
CALCIFIED TISSUE INTERNATIONAL
(2023)
Article
Biochemistry & Molecular Biology
Chakrabhavi Dhananjaya Mohan, Chulwon Kim, Kodappully Sivaraman Siveen, Kanjoormana Aryan Manu, Shobith Rangappa, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Kanchugarakoppal S. Rangappa, Alan Prem Kumar, Kwang Seok Ahn
Summary: Crocetin inhibits STAT3 activation in HCC cells and affects the expression of multiple genes associated with cancer, thereby suppressing cell proliferation and invasive capacity.
Article
Immunology
Lei Shi, Zhen Bian, Koby Kidder, Hongwei Liang, Yuan Liu
Summary: Macrophage functional plasticity is crucial in responding to proinflammatory stimuli. SIRP alpha serves as a key negative regulator of proinflammatory macrophage polarization by activating SHP-1 and inhibiting Akt2, leading to decreased proinflammatory cytokine production and Ag presentation machinery expression.
JOURNAL OF IMMUNOLOGY
(2021)
Review
Oncology
Pei-Jie Chen, Yun-Tian Zhang
Summary: Tyrosine phosphorylation is a reversible process regulated by protein tyrosine kinases and phosphatases. Abnormalities in these proteins, such as PTP1B, can contribute to the development of diseases including cancer. Recent studies have shown that PTP1B plays an important role in cancer initiation and progression, making it a potential target for cancer therapies. This review focuses on the functions and pharmacological effects of PTP1B in different types of cancer.
CURRENT CANCER DRUG TARGETS
(2022)
Article
Plant Sciences
Young Yun Jung, Jae-Young Um, Omaima Nasif, Sulaiman Ali Alharbi, Gautam Sethi, Kwang Seok Ahn
Summary: Leelamine (LEE) inhibits STAT3 phosphorylation and up-stream signaling molecules, leading to cell cycle arrest and enhanced apoptosis in multiple myeloma cells. When used in combination with bortezomib, it synergistically enhances apoptotic actions against MM cells.
Article
Pharmacology & Pharmacy
Paola Orlandi, Marta Banchi, Francesca Vaglini, Marco Carli, Stefano Aringhieri, Arianna Bandini, Carla Pardini, Cristina Viaggi, Michele Lai, Greta Ali, Alessandra Ottani, Eleonora Vandini, Patrizia Guidi, Margherita Bernardeschi, Veronica La Rocca, Giulio Francia, Gabriella Fontanini, Mauro Pistello, Giada Frenzilli, Daniela Giuliani, Marco Scarselli, Guido Bocci
Summary: This study investigates the role of MC4R in melanoma and the use of the selective antagonist ML in combination with vemurafenib. The results show that ML can inhibit melanoma cell proliferation and induce apoptosis through the inhibition of ERK1/2 phosphorylation and reduction of BCL-XL expression. The combination of vemurafenib and ML exhibits a synergistic effect in vitro and inhibits tumor growth in vivo without causing adverse effects.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Conor J. Bloxham, Katina D. Hulme, Fabrizio Fierro, Christian Fercher, Cassandra L. Pegg, Shannon L. O'Brien, Simon R. Foster, Kirsty R. Short, Sebastian G. B. Furness, Melissa E. Reichelt, Masha Y. Niv, Walter G. Thomas
Summary: Bitter taste receptors (T2Rs) are a type of G protein-coupled receptors that allow humans to detect aversive and toxic substances. This study characterized the functional properties of previously identified T2Rs in human cardiac tissues and their naturally occurring polymorphisms. The results showed differences in signaling among different T2R variants, and revealed a potential association between the T2R50 Tyr203 variant and cardiovascular disease.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Lu Chen, Huanying Shi, Wenxin Zhang, Yongjun Zhu, Haifei Chen, Zimei Wu, Huijie Qi, Jiafeng Liu, Mingkang Zhong, Xiaojin Shi, Tianxiao Wang, Qunyi Li
Summary: This study demonstrates that Carfilzomib exhibits potent anti-tumor activity against esophageal squamous cell carcinoma (ESCC) by triggering mitochondrial apoptosis and reprogramming cellular metabolism. It has been identified that activating transcription factor 3 (ATF3) plays a crucial role as a cellular target in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively counteracts the effects of Carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, ATF3 mediates the anti-tumor activity of Carfilzomib, suggesting its potential as a therapeutic agent for ESCC.
BIOCHEMICAL PHARMACOLOGY
(2024)
Review
Pharmacology & Pharmacy
Xing Zhang, Xiang Li, Ran Xia, Hong-Sheng Zhang
Summary: This review summarizes recent progress on the mechanisms of ferroptosis resistance in cancer and highlights the role of redox status and metabolism. Combination therapy for ferroptosis has great potential in treating resistant malignant tumors.
BIOCHEMICAL PHARMACOLOGY
(2024)
